✦ LIBER ✦

Dissociation of recombinant tumor necrosis factor-α studied by gel permeation chromatography

✍ Scribed by Linda Owers Narhi; Tsutomu Arakawa

Book ID: 115760598
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 364 KB
Volume: 147
Category: Article
ISSN: 0006-291X
DOI: 10.1016/0006-291x(87)90992-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activation of bovine neutrophils by reco

Activation of bovine neutrophils by recombinant bovine tumor necrosis factor-α

✍ Yu-Wei Chiang; Hideo Murata; James A. Roth 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 824 KB

One-step refolding and purification of r

One-step refolding and purification of recombinant human tumor necrosis factor- α (rhTNF- α ) using ion-exchange chromatography

✍ Wang, Yan; Ren, Wenxuan; Gao, Dong; Wang, Lili; Yang, Ying; Bai, Quan 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 637 KB

Separation of tumor necrosis factor α is

Separation of tumor necrosis factor α isoforms by two-dimensional polyacrylamide gel electrophoresis

✍ Alan D. Watts; Professor Nicholas H. Hunt; Brett D. Hambly; Geeta Chaudhri 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

Biotinylation Sites of Tumor Necrosis Fa

Biotinylation Sites of Tumor Necrosis Factor-α Determined by Liquid Chromatography–Mass Spectrometry

✍ Fulvio Magni; Flavio Curnis; Laura Marazzini; Roberto Colombo; Angelina Sacchi; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Enhancement of epidermal growth factor r

Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor α

✍ Koji Adachi; Paul Belser; Hans Bender; Derui Li; Ulrich Rodeck; Etty N. Benvenis 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 1014 KB

Phase I study of recombinant human tumor

Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease

✍ T. Moritz; N. Niederle; J. Baumann; D. May; E. Kurschel; R. Osieka; J. Kempeni; 📂 Article 📅 1989 🏛 Springer-Verlag 🌐 English ⚖ 643 KB

A phase I study withrecombinant human tumor necrosis factor a (rhuTNF-a; Knoll AG, Ludwigshafen, FRG) in patients with advanced malignant disease was undertaken to evaluate drug toxicity (organ specifity, time course, predictability, reversibility, maximal tolerated dose), effectiveness, antigenicit